ReviewDrugs2014
Glutamate receptor antagonists in the management of migraine.
Review in Drugs, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Compared to oxcarbazepine and carbamazepine, botulinum toxin type A is a useful therapeutic option for trigeminal neuralgia symptoms: A systematic review.Clinical and experimental dental research · 2024Pooled it
- Astaxanthin as a Therapeutic Candidate for Nociceptive and Inflammatory Pain: Mechanisms and Perspectives.Marine drugs · 2026Review
- Acute Intravenous Astaxanthin Administration Modulates Hyperexcitability in Rat Nociceptive Secondary Sensory Neurons Induced by Inflammation.Marine drugs · 2026Article
- Unmasking the relationship between CGRP and glutamate: from peripheral excitation to central sensitization in migraine.The journal of headache and pain · 2025Review
- The Potential Role of Glutamate Receptors and their Antagonists or Modulators in Migraine Therapy.Current neuropharmacology · 2025Review
- Migraine Treatment: Towards New Pharmacological Targets.International journal of molecular sciences · 2023Review
- Perampanel ameliorates nitroglycerin-induced migraine through inhibition of the cAMP/PKA/CREB signaling pathway in the trigeminal ganglion in rats.The Korean journal of pain · 2023Article
- CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond.Physiological reviews · 2023Review
- Targeting Peripheral N-Methyl-D-Aspartate Receptor (NMDAR): A Novel Strategy for the Treatment of Migraine.Journal of clinical medicine · 2023Review
- Antiseizure Medications for the Prophylaxis of Migraine during the Anti- CGRP Drugs Era.Current neuropharmacology · 2023Review
- Molecular Mechanism of theEvidence-based complementary and alternative medicine : eCAM · 2022Article
- Review
- Approach to Ménière disease management.Canadian family physician Medecin de famille canadien · 2019Review
- Pathophysiological Mechanisms in Migraine and the Identification of New Therapeutic Targets.CNS drugs · 2019Review
- Perampanel inhibits calcitonin gene-related peptide release from rat brainstem in vitro.The journal of headache and pain · 2018Article
- Association between salt substitutes/enhancers and changes in sodium levels in fast-food restaurants: a cross-sectional analysis.CMAJ open · 2018Article
- Recent advances in migraine therapy.SpringerPlus · 2016Review
- Optimal management of Ménière's disease.Therapeutics and clinical risk management · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Migraine is a neurovascular disorder that is associated with severe headache and neurologic symptoms. The pathogenesis of migraine is believed to involve trigeminovascular system activation with the primary dysfunction located in brainstem. Glutamate, the major excitatory neurotransmitter in the central nervous system, and its receptors have since long been suggested in migraine pathophysiology. Different preclinical studies have confirmed their potential role in migraine. Moreover, several glutamate receptor modulators have been studied in clinical studies, some with promising results. In this review, we will give an overview of what is known about the role of glutamate in the pathogenesis of migraine, which will be followed by an overview of available efficacy, safety and tolerability data for glutamate receptor inhibitors in clinical development for the treatment of migraine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.